Johnson & Johnson $JNJ Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in Johnson & Johnson (NYSE:JNJ) by 2.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,802,503 shares of the company’s stock after acquiring an additional 620,039 shares during the period. Johnson & Johnson comprises approximately 0.7% of Bank of New York Mellon Corp’s investment portfolio, making the stock its 20th biggest position. Bank of New York Mellon Corp owned approximately 0.99% of Johnson & Johnson worth $3,635,832,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter valued at $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on JNJ shares. UBS Group boosted their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Raymond James Financial lifted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Citigroup upped their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

NYSE JNJ opened at $189.02 on Monday. The business’s fifty day simple moving average is $183.28 and its 200-day simple moving average is $167.75. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $455.40 billion, a PE ratio of 18.25, a P/E/G ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.